The effect of DPP-4 inhibitors therapy on the left atrial volume index in patients with type 2 diabetes mellitus

被引：0
|
作者：
Papazafiropoulou, A. K. [1 ,2 ]
Trikkalinou, A. [1 ,2 ]
Ganotopoulou, A. [1 ,2 ]
Kasinos, N. [3 ]
Ioannidis, C. [3 ]
Tountas, C. [3 ]
Foussas, S. [3 ]
Melidonis, A. [1 ,2 ]
机构：
[1] Tzaneio Gen Hosp, Dept Internal Med 1, Piraeus, Greece
[2] Tzaneio Gen Hosp, Ctr Diabet, Piraeus, Greece
[3] Tzaneio Gen Hosp, Dept Cardiol, Piraeus, Greece
来源：
ARCHIVES OF HELLENIC MEDICINE | 2016年 / 33卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：708 / +
页数：2
相关论文
共 50 条
  • [21] Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
    S., Ametov A.
    Karpova, E., V
    DIABETES MELLITUS, 2010, 13 (02): : 69 - 75
  • [22] The Effect of DPP-4 Inhibitor, Alogliptin, on Bone Metabolism in Patients With Type 2 Diabetes Mellitus
    Yamauchi, Yuichiro
    Tunekawa, Shin
    Seino, Yusuke
    Uenishi, Eita
    Okawa, Tetuji
    Fujiya, Atushi
    Ishikawa, Kouta
    Ogata, Hidetada
    Iida, Atushi
    Banno, Ryoichi
    Arima, Hiroshi
    Hamada, Yoji
    Oiso, Yutaka
    DIABETES, 2013, 62 : A276 - A277
  • [23] The influence of DPP-4 inhibitors on fat metabolism in type 2 diabetes patients
    Ametov, A. S.
    Gusenbekova, D. G.
    DIABETOLOGIA, 2014, 57 : S378 - S378
  • [24] An update on DPP-4 inhibitors in the management of type 2 diabetes
    Cahn, Avivit
    Cernea, Simona
    Raz, Itamar
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (04) : 409 - 419
  • [25] The Clinical Efficacy and Treatment Satisfaction of Weekly DPP-4 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus
    Tosaki, Takahiro
    Kamiya, Hideki
    Himeno, Tatsuhito
    Kato, Yoshiro
    Kondo, Masaki
    Inagaki, Akemi
    Yamamoto, Yuka
    Mizubayashi, Ryuichi
    Tsubonaka, Kaori
    Oshiro, Chie
    Nakaya, Yuki
    Nakamura, Jiro
    DIABETES, 2016, 65 : A300 - A300
  • [26] A Clinical Overview of DPP-4 Inhibitors for Type 2 Diabetes
    Jeon, Michelle
    Took, Roxane L.
    Peters, Golden L.
    US PHARMACIST, 2018, 43 (10) : 49 - 56
  • [27] DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship
    Mohammed Alrouji
    Hayder M. Al-kuraishy
    Ali K. Al-buhadily
    Ali I. Al-Gareeb
    Engy Elekhnawy
    Gaber El-Saber Batiha
    Pharmacological Reports, 2023, 75 : 923 - 936
  • [28] DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship
    Alrouji, Mohammed
    Al-kuraishy, Hayder M.
    Al-buhadily, Ali K.
    Al-Gareeb, Ali I.
    Elekhnawy, Engy
    Batiha, Gaber El-Saber
    PHARMACOLOGICAL REPORTS, 2023, 75 (04) : 923 - 936
  • [29] Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors
    Wu, Mei-zhen
    Teng, Tiew-Hwa Katherine
    Tsang, Christopher Tze-Wei
    Chan, Yap-Hang
    Lee, Chi-Ho
    Ren, Qing-wen
    Huang, Jia-Yi
    Cheang, Iok-fai
    Tse, Yi-Kei
    Li, Xin-li
    Xu, Xin
    Tse, Hung-Fat
    Lam, Carolyn S. P.
    Yiu, Kai-Hang
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2024, 10 (01) : 45 - 52
  • [30] THE COMPARISON OF SGLT2 INHIBITORS AND DPP-4 INHIBITORS ON HEALTH CARE EXPENDITURE AND UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Wagner, T.
    Dixon, D. L.
    Salgado, T. M.
    VALUE IN HEALTH, 2020, 23 : S117 - S117
12345